Anti-psoriatic drug anthralin activates JNK via lipid peroxidation: Mononuclear cells are more sensitive than keratinocytes

Journal of Investigative Dermatology

Volumn 114, Issue 4, 2000, Pages 688-692

  Peus, Dominik ^a,b   Beyerle, Astrid ^a   Rittner, Heike L ^a   Pott, Markus ^a   Meves, Alexander ^a   Weyand, Cornelia ^a   Pittelkow, Mark R ^a  

^a MAYO CLINIC   (United States)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Anthralin; C jun N terminal protein kinase; Keratinocytes; Lipid peroxidation; Reactive oxygen species

Indexed keywords

ANTIPSORIASIS AGENT; DITHRANOL; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; KERATINOCYTE; LIPID PEROXIDATION; MONONUCLEAR CELL; PRIORITY JOURNAL; PSORIASIS; SIGNAL TRANSDUCTION;

EID: 0034001007     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2000.00934.x     Document Type: Article

References (32)

1. Bata-Csorgo Z, Hammerberg C, Voorhees JJ, Cooper KD: Intralesional T-lymphocyte activation as a mediator of psoriatic epidermal hyperplasia. J Invest Dermatol 105:89S-94S, 1995
2. Busciglio J, Yankner BA: Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378:776-779, 1995
3. Christophers E, Mrowietz U: The inflammatory infiltrate in psoriasis. Clin Dermatol 13:131-135, 1995
4. Davis RJ: Signal transduction by the c-Jun N-terminal kinase. Biochem Soc Symp 64:1-12, 1999
5. Derijard B, Hibi M, Wu IH, et al: JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76:1025-1037, 1994
6. Finnen MJ, Lawrence CM, Shuster S: Inhibition of dithranol inflammation by free-radical scavengers. Lancet ii:1129-1130, 1984
7. Galewsky E: Über Cignolin, ein Ersatzpräparat des Chrysarobins. Dermatol Wochenschr 62:113-115, 1916
8. Guttteridge JM, Halliwell B: Iron toxicity and oxygen radicals. Baillière Clin Haematol 2:195-256, 1989
9. Hedley D, Chow S: Flow cytometric measurement of lipid peroxidation in vital cells using parinaric acid. Cytometry 13:686-692, 1992
10. Hibi M, Lin A, Smeal T, Minden A, Karin M: Identification of an oncoprotein-and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Development 7:2135-2148, 1993
11. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ: Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75:241-251, 1993
12. Jeffes EW, 3rd, McCullough JL, Pittelkow MR, et al: Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 104:183-188, 1995
13. Johnson R, Staiano-Coico L, Austin L, Cardinale I, Nabeya-Tsukifuji R, Krueger JG: PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in human T-lymphocytes. Photochem Photobiol 63:566-571, 1996
14. Kemeny L, Ruzicka T, Braun-Falco O: Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol 3:1-20, 1990
15. Krueger JG, Wolfe JT, Nabeya RT, et al: Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 182:2057-2068, 1995
16. Kuypers FA, van den Berg JJ, Schalkwijk C, Roelofsen B, Op den Kamp JA: Parinaric acid as a sensitive fluorescent probe for the determination of lipid peroxidation. Biochim Biophys Acta 921:266-274, 1987
17. Lo YYC, Wong JMS, Cruz TF: Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. J Biol Chem 271:15703-15707, 1996
18. Mahrle G: Dithranol. Clin Dermatol 15:723-737, 1997
19. Mrowietz U, Jessat H, Schwarz A, Schwarz T: Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-α, but not IL-1. Br J Dermatol 136:542-547, 1997
20. Muller K: Antipsoriatic and proinflammatory action of anthralin. Implications for the role of oxygen radicals. Biochem Pharmacol 53:1215-1221, 1997
21. Muller K, Prinz H: Antipsoriatic anthrones with modulated redox properties. 4. Synthesis and biological activity of novel 9,10-dihydro-1,8-dihydroxy-9-oxo-2-anthracenecarboxylic and -hydroxamic acids. J Med Chem 40:2780-2787, 1997
22. Peus D, Hamacher L, Pittelkow MR: EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation. J Invest Dermatol 109:751-756, 1997
23. Reichert U, Jacques Y, Grangeret M, Schmidt R: Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes. J Invest Dermatol 84:130-134, 1985
24. Schaefer H, Schalla W, Shroot B: Anthralin-facts, trends and unresolved problems. Z Hautkr 146:273-282, 1981
25. Schallreuter KU, Pittelkow MR: Anthralin inhibits elevated levels of thioredoxin reductase in psoriasis. A new mode of action for this drug. Arch Dematol 123:1494-1498, 1987
26. Schon MP, Detmar M, Parker CM: Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat Med 3:183-188, 1997
27. Schroder JM: Anthralin (1,8-dihydroxyanthrone) is a potent inhibitor of leukotriene production and LTB4-omega oxidation by human neutrophils. J Invest Dermatol 87:624-629, 1986
28. Schroder JM, Kosfeld U, Christophers E: Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils. J Invest Dermatol 85:30-34, 1985
29. Stern RS: Psoriasis. Lancet 350:349-353, 1997
30. Unna PG: Cignolin als Heilmittel der Psoriases. Dermatol Wochenschr 62:116-137, 150-163, 175-183, 1916
31. Veis DJ, Sorenson CM, Shutter JR, Korsmeyer SJ: Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75:229-240, 1993
32. Whitefield M, Leeder GM, Mosedale AR: Inhibition of dithranol inflammation by free-radical scavengers. Lancet i:173, 1985